ORIC

MKT CAP:$1B

ORIC Pharmaceuticals, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$10.43+$2.26 (+27.66%)

Apr 23, 2026

Company Details

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small mol...

CEO

Jacob Chacko

IPO Date

Apr 24, 2020

Website

www.oricpharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$129M

EPS (Diluted)

-$1.52

Free Cash Flow

-$112M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 4, 2026

PENDING

FY 2025

Feb 23, 2026

$0EPS -$1.47

Q4 2025

Feb 23, 2026

$0EPS -$0.30

Q3 2025

Nov 13, 2025

$0EPS -$0.33

Q2 2025

Aug 12, 2025

$0EPS -$0.47

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$23M
Q2 22	$0	$0	-$21M
Q3 22	$0	$0	-$26M
Q4 22	$0	$0	-$22M
Q1 23	$0	$0	-$26M
Q2 23	$0	$0	-$25M
Q3 23	$0	$0	-$29M
Q4 23	$0	-$263.0K	-$31M
Q1 24	$0	-$261.0K	-$29M
Q2 24	$0	$0	-$36M
Q3 24	$0	$0	-$38M
Q4 24	$0	-$304.0K	-$40M
Q1 25	$0	$0	-$33M
Q2 25	$0	$0	-$39M
Q3 25	$0	$0	-$37M
Q4 25	$0	-$320.0K	-$35M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$23M	-$23M
Q2 22	-$18M	-$18M
Q3 22	-$19M	-$20M
Q4 22	-$15M	-$16M
Q1 23	-$21M	-$21M
Q2 23	-$21M	-$22M
Q3 23	-$20M	-$20M
Q4 23	-$24M	-$24M
Q1 24	-$30M	-$31M
Q2 24	-$26M	-$26M
Q3 24	-$29M	-$29M
Q4 24	-$28M	-$28M
Q1 25	-$33M	-$33M
Q2 25	-$31M	-$31M
Q3 25	-$25M	-$25M
Q4 25	-$22M	-$23M

Capital Expenditures

Quarter	CapEx
Q1 22	$723.0K
Q2 22	$667.0K
Q3 22	$401.0K
Q4 22	$287.0K
Q1 23	$310.0K
Q2 23	$405.0K
Q3 23	$77.0K
Q4 23	$57.0K
Q1 24	$218.0K
Q2 24	$333.0K
Q3 24	$418.0K
Q4 24	$219.0K
Q1 25	$387.0K
Q2 25	$63.0K
Q3 25	$35.0K
Q4 25	$387.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+40.5%
Q2 22	—	-1.7%
Q3 22	—	+39.2%
Q4 22	—	-3.0%
Q1 23	—	+10.4%
Q2 23	—	+20.8%
Q3 23	—	+11.6%
Q4 23	—	+42.1%
Q1 24	—	+12.9%
Q2 24	—	+44.1%
Q3 24	—	+33.6%
Q4 24	—	+25.9%
Q1 25	—	+12.9%
Q2 25	—	+8.5%
Q3 25	—	-4.3%
Q4 25	—	-12.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	—
Q2 22	$4M	—
Q3 22	$3M	—
Q4 22	$3M	—
Q1 23	$4M	—
Q2 23	$4M	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	$5M	—
Q2 24	$5M	—
Q3 24	$5M	—
Q4 24	$5M	—
Q1 25	$0	—
Q2 25	$7M	—
Q3 25	$6M	—
Q4 25	$6M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$17M	$6M	—
Q2 22	$14M	$7M	—
Q3 22	$15M	$6M	—
Q4 22	$16M	$6M	—
Q1 23	$20M	$6M	—
Q2 23	$19M	$6M	—
Q3 23	$22M	$6M	—
Q4 23	$24M	—	$7M
Q1 24	$22M	$7M	—
Q2 24	$29M	$7M	—
Q3 24	$31M	$7M	—
Q4 24	$32M	—	$7M
Q1 25	$25M	$8M	—
Q2 25	$31M	$9M	—
Q3 25	$29M	$8M	—
Q4 25	$26M	$9M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$113M	$122M	$235M
Q2 22	$49M	$178M	$227M
Q3 22	$29M	$165M	$194M
Q4 22	$67M	$139M	$206M
Q1 23	$59M	$131M	$190M
Q2 23	$104M	$160M	$264M
Q3 23	$26M	$201M	$227M
Q4 23	$23M	$185M	$208M
Q1 24	$56M	$260M	$317M
Q2 24	$50M	$237M	$286M
Q3 24	$44M	$228M	$272M
Q4 24	$59M	$197M	$256M
Q1 25	$49M	$154M	$204M
Q2 25	$76M	$207M	$283M
Q3 25	$50M	$237M	$287M
Q4 25	$46M	$236M	$281M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	39M	+0.1%	+7.5%
Q2 22	39M	+0.1%	+7.6%
Q3 22	40M	+0.2%	+1.5%
Q4 22	40M	+1.4%	+1.9%
Q1 23	45M	+12.4%	+14.3%
Q2 23	46M	+1.3%	+15.6%
Q3 23	57M	+25.7%	+45.0%
Q4 23	57M	+0.1%	+43.2%
Q1 24	67M	+17.2%	+49.4%
Q2 24	70M	+4.5%	+54.1%
Q3 24	71M	+0.3%	+22.9%
Q4 24	71M	+0.2%	+22.9%
Q1 25	71M	+0.5%	+5.5%
Q2 25	78M	+10.0%	+11.1%
Q3 25	99M	+26.7%	+40.3%
Q4 25	88M	-11.3%	+24.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	78
Q2 22	$0	78
Q3 22	$0	78
Q4 22	$0	86
Q1 23	$0	86
Q2 23	$0	86
Q3 23	$0	86
Q4 23	$0	100
Q1 24	$0	100
Q2 24	$0	100
Q3 24	$0	100
Q4 24	$0	115
Q1 25	$0	115
Q2 25	$0	115
Q3 25	$0	115
Q4 25	$0	200K

Revenue / Employee